NeuroPace to Present Data from Studies of the RNS System at American Academy of Neurology 2019 Annual Meeting
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--May 2, 2019--NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced that data from two studies of the company’s RNS ® System for adults with medically refractory focal onset epilepsy will be presented at the American Academy of Neurology (AAN) 2019 Annual Meeting taking place May 4-10 in Philadelphia.
Results from the company’s groundbreaking Long-Term Treatment Study of the RNS System, the largest and longest prospective neuromodulation study, will be presented by principal investigator Dileep Nair, MD, section head of adult epilepsy, Cleveland Clinic Neurological Institute.
In addition, new research data evaluating whether objective epilepsy biomarkers derived from interictal electrocorticographic (ECoG) data can be used to identify mesiotemporal lobe epilepsy (MTL) patients who respond to treatment with the NeuroPace RNS System will be presented by Sharanya Arcot Desai, Ph.D., senior research scientist at NeuroPace.
Nine-year Prospective Safety and Effectiveness Outcomes from the Long-Term Treatment Trial of the RNS
Presented by principal investigator Dileep Nair, M.D.
Wednesday, May 8th, 1:44 p.m. ET, S36.005
Interictal Electrographic Features Differentiate MTL Responders and Nonresponders
Presented by Sharanya Arcot Desai, Ph.D.
Thursday, May 9th, 1:00 p.m. ET, S48.001
About the RNS ® System
The RNS System is the world’s first and only closed-loop brain-responsive neurostimulation system designed to prevent epileptic seizures at their source. As a type of brain-computer interface, the RNS System treats seizures by continuously monitoring brain waves, recognizing each patient’s unique “seizure onset fingerprint,” and automatically responding with imperceptible electrical pulses before seizures occur. The RNS System is composed of a neurostimulator, leads that are placed at the seizure foci, a remote monitor used by patients to upload their data, and a RNS Tablet and Patient Data Management System (PDMS) used by physicians. Physicians can view their patient’s electrographic data on a secure website and program the device to personalize therapy for each individual. Unlike anti-epileptic drugs or resective surgery, brain-responsive neuromodulation outcomes typically improve with time and do not cause the cognitive side effects that can be associated with those alternatives. The RNS System is now available at nearly all comprehensive epilepsy centers in the United States and is widely covered by private and government insurance.
The RNS ® System is an adjunctive therapy for adults with refractory, focal onset seizures with no more than 2 epileptogenic foci. See important safety information at www.neuropace.com/safety/.
NeuroPace is the global leader in the emerging field of brain-computer interface technologies, which is projected to become a $1.2 billion market by 2024. We are dedicated to developing groundbreaking technology and advancing brain science to improve the quality of life for millions of individuals who suffer from neurological disorders. The company’s first product, the RNS System, is the only FDA-approved brain-responsive neurostimulator for the treatment of focal onset refractory epilepsy. In addition to treating epilepsy, brain-responsive neuromodulation holds the promise of treating other brain disorders that impact quality of life for millions of patients throughout the world.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190502005853/en/
CONTACT: Durae Hardy
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA PENNSYLVANIA
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS MEDICAL DEVICES RESEARCH SCIENCE
SOURCE: NeuroPace, Inc.
Copyright Business Wire 2019.
PUB: 05/02/2019 03:30 PM/DISC: 05/02/2019 03:30 PM